|
Pronunciation |
|
(bel
a DON
a) |
|
|
Generic
Available |
|
Yes |
|
|
Pharmacological Index |
|
Anticholinergic Agent |
|
|
Use |
|
Decrease gastrointestinal activity in functional bowel disorders; delay
gastric emptying as well as decrease gastric secretion |
|
|
Pregnancy Risk
Factor |
|
C |
|
|
Contraindications |
|
Hypersensitivity to belladonna or any components; glaucoma, elevated
intraocular pressure; significant hepatic or renal disease; pulmonary
insufficiency |
|
|
Adverse
Reactions |
|
>10%:
Dermatologic: Dry skin
Gastrointestinal: Constipation, dry throat, xerostomia
Respiratory: Dry nose
Miscellaneous: Decreased diaphoresis
1% to 10%:
Dermatologic: Increased sensitivity to light
Endocrine & metabolic: Decreased flow of breast milk, dysphagia
|
|
|
Drug
Interactions |
|
Phenothiazines, amantadine, antiparkinsonian drugs, glutethimide, meperidine,
tricyclic antidepressants, antiarrhythmic agents, some
antihistamines |
|
|
Stability |
|
Store in tight, light-resistant container at 15°C to
30°C |
|
|
Mechanism of
Action |
|
Belladonna is a mixture of the anticholinergic alkaloids atropine,
hyoscyamine, and scopolamine (hyoscine). The belladonna alkaloids act primarily
by competitive inhibition of the muscarinic actions of acetylcholine on
structures innervated by postganglionic cholinergic neurons and on smooth
muscle. The resulting effects include antisecretory activity on exocrine glands
and intestinal mucosa and smooth muscle relaxation. The anticholinergic
properties of scopolamine and atropine differ in that scopolamine has a more
potent activity on the iris, ciliary body, and certain secretory glands; has
more potent activity on the heart, intestine, and bronchial muscle, and a more
prolonged duration of action; in contrast, hyoscyamine has actions similar to
those of atropine, but is more potent in both its central and peripheral
effects |
|
|
Usual Dosage |
|
Tincture: Oral:
Adults: 0.6-1 mL 3-4 times/day |
|
|
Mental Health: Effects
on Mental Status |
|
May cause drowsiness; rare reports of confusion |
|
|
Mental Health:
Effects on Psychiatric
Treatment |
|
Concurrent use with psychotropics may produce additive sedation; may decrease
the effects of phenothiazines; concurrent use with psychotropics may result in
additive anticholinergic side effects (dry mouth, blurred vision,
constipation) |
|
|
Dental Health: Local
Anesthetic/Vasoconstrictor
Precautions |
|
No information available to require special precautions |
|
|
Dental Health:
Effects on Dental Treatment |
|
>10% of patients experience dry mouth |
|
|
Patient
Information |
|
May cause drowsiness and blurred vision |
|
|
Nursing
Implications |
|
Monitor CNS depression; assist patient with ambulation |
|
|
Dosage Forms |
|
Tincture: Belladonna alkaloids (principally hyoscyamine and atropine) 0.3
mg/mL with alcohol 65% to 70% (120 mL, 480 mL, 3780
mL) |
|
Copyright © 1978-2000 Lexi-Comp Inc. All Rights Reserved
|